Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital

Serum IL6 as a Prognostic Biomarker and IL6R as a Therapeutic Target in Biliary Tract Cancers

Research output: Contribution to journalJournal articleResearchpeer-review

  1. The Number of Signaling Pathways Altered by Driver Mutations in Chronic Lymphocytic Leukemia Impacts Disease Outcome

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Phase 2 study of the Exportin 1 inhibitor selinexor in patients with recurrent gynecological malignancies

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Dan Høgdall
  • Colm J O'Rourke
  • Christian Dehlendorff
  • Ole F Larsen
  • Lars H Jensen
  • Astrid Z Johansen
  • Hien Dang
  • Valentina M Factor
  • Mie Grunnet
  • Morten Mau-Sørensen
  • Douglas V N P Oliveira
  • Dorte Linnemann
  • Mogens K Boisen
  • Xin W Wang
  • Julia S Johansen
  • Jesper B Andersen
View graph of relations

PURPOSE: Biliary tract cancer (BTC) is a heterogeneous group of rare gastrointestinal malignancies with dismal prognosis often associated with inflammation. We assessed the prognostic value of IL6 and YKL-40 compared with CA19-9 before and during palliative chemotherapy. We also investigated in mice whether IL6R inhibition in combination with gemcitabine could prolong chemosensitivity.

EXPERIMENTAL DESIGN: A total of 452 Danish participants with advanced (locally advanced and metastatic) BTC were included from six clinical trials (February 2004 to March 2017). Serum CA19-9, IL6, and YKL-40 were measured before and during palliative treatment. Associations between candidate biomarkers and progression-free survival (PFS) and overall survival (OS) were analyzed by univariate and multivariate Cox regression. Effects of inhibiting IL6R and YKL-40 were assessed in vitro, and of IL6R inhibition in vivo.

RESULTS: High pretreatment levels of CA19-9, IL6, and YKL-40, and increasing levels during treatment, were associated with short PFS and OS in patients with advanced BTC. IL6 provided independent prognostic information, independent of tumor location and in patients with normal serum CA19-9. ROC analyses showed that IL6 and YKL-40 were predictive of very short OS (OS < 6 months), whereas CA19-9 was best to predict OS > 1.5 years. Treatment with anti-IL6R and gemcitabine significantly diminished tumor growth when compared with gemcitabine monotherapy in an in vivo transplant model of BTC.

CONCLUSIONS: Serum IL6 and YKL-40 are potential new prognostic biomarkers in BTC. IL6 provides independent prognostic information and may be superior to CA19-9 in certain contexts. Moreover, anti-IL6R should be considered as a new treatment option to sustain gemcitabine response in patients with BTC.

Original languageEnglish
JournalClinical Cancer Research
Issue number21
Pages (from-to)5655-5667
Number of pages13
Publication statusPublished - 1 Nov 2020

ID: 61014121